Author
Mayo ClinicORCID 0000-0001-6510-305XUnclaimed ORCID profile · follow to get notified of new preprints
3 papers
Recent·Most cited
Enis H. Ozmert, Jennifer Tomlinson, Ryan D. Watkins…·Rory L. Smoot
The paper identifies LCK-driven EGFR activation as a therapeutic target in cholangiocarcinoma, showing EGFR activity predicts response to EGFR inhibition.
Jack W. Sample, Enis Özmert, Brandon A. Wilbanks…·Rory L. Smoot
This study identifies AKT as a regulator of YAP stability and shows that AKT inhibition triggers ESCRT-dependent YAP degradation, enhancing the efficacy of RAS inhibition in pancreatobiliary cancers.
Hendrien Kuipers, Danielle Marie Carlson, Erik Jessen…·Rory L. Smoot
This study identifies biomarkers and resistance mechanisms to SFK-YAP inhibition in cholangiocarcinoma using multiomic profiling and shows synergy with chemotherapy.